Diets & Weight Loss

Neoplasm

A tumor

Question: In using the neoplasm table, what do you do when there is no code in cancer in situ? When using the neoplasm table in the ICD-9-CM, how would one code cancer in situ of the temporal lobe?

Answer: You'll never find it there. What you're probably looking for is under skin: Ca in situ of temple or similar.

 


Neoplasm Related Products and News

A 54-year-old woman with bilateral hydronephrosis

Healio
She underwent CT-guided biopsy of her pelvic lymphadenopathy. Fine-needle aspiration biopsy of the retroperitoneal mass revealed a malignant neoplasm with hyperchromatic pleomorphic cells with nuclear molding and necrosis. The cells were negative for ...
 

There's a Code for That

ICD10monitor
Suppose you were initially diagnosed with cancer in the upper outer quadrant of your right breast, then find that you additionally have a new benign neoplasm in the left breast. Today, laterality is not inherent in the diagnosis coding choices. Some ...
 

Classification of Thymic Epithelial Neoplasms Is Still a Challenge to Thoracic ...

Insurance News Net
Thymic squamous cell carcinoma is the most common presentation. Because of the infrequency of these neoplasms and their heterogeneity, rates of interobserver and intraobserver reproducibility of diagnosis according to the WHO classification are ...
 

Stemline Therapeutics Inc.: Stemline Therapeutics Provides Second Quarter ...

The Wall Street Transcript
Opened multicenter trial with SL-401 in advanced blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML). Stemline has opened a multicenter, open-label study in BPDCN and AML. The trial will include a brief lead-in that ...
 

FDA Approves First Artificial Tumor

The Onion (satire)
?There were obviously significant complications in devising a tumor substitute the human body would accept, but we now have an artificial neoplasm that serves the same physiological functions as an organic abnormal growth of tissue,? said Jeffrey ...
 

Stemline Therapeutics to Present at the Wedbush Life Sciences Management ...

MarketWatch
SL-401 has demonstrated single-agent activity, including durable complete responses (CRs), in a Phase 1/2 trial in several indications including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed or refractory acute myeloid leukemia (AML).
 

NorthJersey.com

Rutherford's CGI gets up close and personal about cancer
NorthJersey.com
 

FDA Grants Priority Review to Ruxolitinib in Polycythemia Vera

OncLive
The rates of grade 3/4 anemia and thrombocytopenia were less in the ruxolitinib arm compared with best available therapy (1.8% vs 5.5% and 0% vs 3.6%, respectively). Symptom improvement by Myeloproliferative Neoplasm Symptom Assessment Form ...
 

Prediction Tool for Readmissions Due to End-of-Life Care

The Hospitalist Online
The four factors that were significantly associated with 30-day PAR for end-of-life care issues were: neoplasm (OR 5.6, 95% CI: 2.85-11.0), opiate medication at discharge (OR 2.29, 95% CI: 1.29-4.07), Elixhauser comorbidity index, per five-unit ...
 

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 ...

CNNMoney
Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. Pacritinib may offer an advantage over other JAK inhibitors ...